Zoetis Inc. (ZTS)
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zoetis: Deep Value Persists
Zoetis offers broad diversification across hundreds of animal health products, with nearly equal U.S. and international revenue exposure. ZTS posted resilient Q4 2025 results, with 3% revenue growth, 5.7% EPS growth, and a robust 27%+ non-GAAP net margin, outperforming consensus. Key 2026 catalysts include launches of next-generation osteoarthritis drugs Portela and Lenivia, targeting improved compliance and expanded market reach.
Zoetis: Still Not Cheap Near 5-Year Lows
Zoetis Inc. (ZTS) is rated a hold, as shares trade near fair value with limited upside despite sector leadership and defensive qualities. The company guides for 3-5% organic operational growth in 2026 and remains very shareholder-friendly, reflected in a 20% 5-year DPS growth and 6.6% buyback yield. Zoetis faces risks from pipeline concentration, potential margin pressure due to increasing competition and product setbacks, notably Librela's 32% sales decline due to safety concerns.
Zoetis (ZTS) Falls More Steeply Than Broader Market: What Investors Need to Know
In the most recent trading session, Zoetis (ZTS) closed at $113.35, indicating a -2.81% shift from the previous trading day.
Zoetis (ZTS) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wall Street Analysts See Zoetis (ZTS) as a Buy: Should You Invest?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Zoetis Inc. (ZTS) Presents at 2026 KeyBanc Capital Markets Healthcare Forum Transcript
Zoetis Inc. (ZTS) Presents at 2026 KeyBanc Capital Markets Healthcare Forum Transcript
Zoetis Inc. $ZTS Shares Purchased by California Public Employees Retirement System
California Public Employees Retirement System increased its holdings in shares of Zoetis Inc. (NYSE: ZTS) by 39.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,654,423 shares of the company's stock after buying an additional 466,299 shares
Ameriprise Financial Inc. Grows Position in Zoetis Inc. $ZTS
Ameriprise Financial Inc. raised its position in Zoetis Inc. (NYSE: ZTS) by 3.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,292,836 shares of the company's stock after purchasing an additional 112,843 shares during the quarter. Ameriprise Financial Inc. owned 0.75%
Zoetis Inc. $ZTS Shares Sold by Brown Brothers Harriman & Co.
Brown Brothers Harriman and Co. cut its position in shares of Zoetis Inc. (NYSE: ZTS) by 2.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,875,126 shares of the company's stock after selling 43,385 shares during the period. Zoetis
Zoetis: The King Of Animal Health On Sale
Zoetis Inc. (ZTS) is a wide-moat animal health leader, rated BUY due to strong fundamentals and undervaluation despite industry-leading profitability. Zoetis trades at a forward P/E of 17.28x, below both S&P 500 and weaker rival Elanco, with a target price of $150 implying 25% upside. Risks center on Librela/Solensia safety concerns, with FDA post-marketing study results in 1H 2026 being a critical near-term catalyst.
Zoetis (ZTS) Loses 8.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Zoetis (ZTS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
